TrialRespiratory research2016

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.

Leonardo M Fabbri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.